Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives

European Urology

Volumn 69, Issue 5, 2016, Pages 775-787

  Bayne, Christopher E ^a   Williams, Stephen B ^b   Cooperberg, Matthew R ^c   Gleave, Martin E ^d   Graefen, Markus ^e   Montorsi, Francesco ^f   Novara, Giacomo ^g   Smaldone, Marc C ^h   Sooriakumaran, Prasanna ^i,j   Wiklund, Peter N ⁱ   Chapin, Brian F ^b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

^h TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

Chemotherapy; Neoplasm metastasis; Prostatectomy; Prostatic neoplasms; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CYTOREDUCTIVE SURGERY; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LOCAL THERAPY; MEDLINE; METASTASIS; METASTATIC PROSTATE CANCER; MULTIMODALITY CANCER THERAPY; OCCULT NODAL DISEASE; OUTCOME ASSESSMENT; PATIENT RISK; PATIENT SELECTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RETROSPECTIVE STUDY; REVIEW; SCOPUS; SYSTEMIC THERAPY; TUMOR GROWTH; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; PATHOLOGY; PROSTATE TUMOR; PROSTATECTOMY; RADIOTHERAPY; RISK ASSESSMENT;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYTOREDUCTION SURGICAL PROCEDURES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; RISK ASSESSMENT;

EID: 84929643381     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.04.036     Document Type: Review

References (77)

1. G. De Angelis, H.G. Rittenhouse, S.D. Mikolajczyk, and et al. Twenty years of PSA: from prostate antigen to tumor marker Rev Urol 9 2007 113 123
2. J.N. Wu, K.M. Fish, C.P. Evans, R.W. Devere White, and M.A. Dall'Era No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period Cancer 120 2014 818 823
3. C.M. Tangen, M.H. Hussain, C.S. Higano, and et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346) J Urol 188 2012 1164 1169
4. A. Heidenreich, P.J. Bastian, J. Bellmunt, and et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 65 2014 467 479
5. National Comprehensive Cancer Network. Prostate cancer (Version 2.2014). http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf
6. C. Sweeney, Y.H. Chen, M.A. Carducci, and et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial J Clin Oncol 32 Suppl 5 2014 LBA2
7. I.M. Thompson, C.M. Tangen, J. Paradelo, and et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial J Urol 181 2009 956 962
8. M. Bolla, H. van Poppel, B. Tombal, and et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) Lancet 380 2012 2018 2027
9. T. Wiegel, D. Bartkowiak, D. Bottke, and et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial Eur Urol 66 2014 243 250
10. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 2002 1248 1259
11. O. Glehen, F. Mohamed, and F.N. Gilly Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia Lancet Oncol 5 2004 219 228
12. L.K. Temple, L. Hsieh, W.D. Wong, L. Saltz, and D. Schrag Use of surgery among elderly patients with stage IV colorectal cancer J Clin Oncol 22 2004 3475 3484
13. G.H. Mickisch, A. Garin, H. van Poppel, and et al. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 2001 966 970
14. R.C. Flanigan, S.E. Salmon, B.A. Blumenstein, and et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659
15. I.M. Thompson, C. Tangen, J. Basler, and E.D. Crawford Impact of previous local treatment for prostate cancer on subsequent metastatic disease J Urol 168 2002 1008 1012
16. R.E. Millikan, S. Wen, L.C. Pagliaro, and et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer J Clin Oncol 26 2008 5936 5942
17. D. Kadmon, W.D. Heston, and W.R. Fair Treatment of a metastatic prostate derived tumor with surgery and chemotherapy J Urol 127 1982 1238 1242
18. G. Grinis, P. Targonski, M. Shaw, M. Rubenstein, and P.D. Guinan Cytoreductive surgery impedes metastasis and enhances the immune response: a preliminary report J Surg Oncol 48 1991 122 126
19. X.J. Qin, C.G. Ma, D.W. Ye, and et al. Tumor cytoreduction results in better response to androgen-ablation - a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer Urol Oncol 30 2012 145 149
20. R.N. Kaplan, S. Rafii, and D. Lyden Preparing the "soil": the premetastatic niche Cancer Res 66 2006 11089 11093
21. M.C. Haffner, T. Mosbruger, D.M. Esopi, and et al. Tracking the clonal origin of lethal prostate cancer J Clin Invest 123 2013 4918 4922
22. J. Lindberg, A. Kristiansen, P. Wiklund, H. Grönberg, and L. Egevad Tracking the origin of metastatic prostate cancer Eur Urol 67 2015 819 822
23. M.Y. Kim, T. Oskarsson, S. Acharyya, and et al. Tumor self-seeding by circulating cancer cells Cell 139 2009 1315 1326
24. D. Weckermann, B. Polzer, T. Ragg, and et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer J Clin Oncol 27 2009 1549 1556
25. J.M. Crook, S. Malone, G. Perry, and et al. Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial Cancer 115 2009 673 679
26. V. Tzelepi, E. Efstathiou, S. Wen, and et al. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment J Clin Oncol 29 2011 2574 2581
27. A. Widmark, O. Klepp, A. Solberg, and et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial Lancet 373 2009 301 308
28. P. Warde, M. Mason, K. Ding, and et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial Lancet 378 2011 2104 2111
29. N. Mottet, M. Peneau, J.J. Mazeron, V. Molinie, and P. Richaud Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial Eur Urol 62 2012 213 219
30. A.J. Stephenson, M. Bolla, A. Briganti, and et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy Eur Urol 61 2012 443 451
31. H.A. Frazier II, J.E. Robertson, and D.F. Paulson Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival? World J Urol 12 1994 308 312
32. H.G. Frohmüller, M. Theiss, A. Manseck, and et al. Survival and quality of life of patients with stage D1 (T1-3 pN1-2 M0) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone Eur Urol 27 1995 202 206
33. J.A. Cadeddu, A.W. Partin, J.I. Epstein, and P.C. Walsh Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy Urology 50 1997 251 255
34. R. Ghavamian, E.J. Bergstralh, M.L. Blute, J. Slezak, and H. Zincke Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison J Urol 161 1999 1223 1227
35. G.K. Zagars, A. Pollack, and A.C. von Eschenbach Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer Urology 58 2001 233 239
36. J. Engel, P.J. Bastian, H. Baur, and et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer Eur Urol 57 2010 754 761
37. T. Steuber, L. Budäus, J. Walz, and et al. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study BJU Int 107 2011 1755 1761
38. S. Daneshmand, M.L. Quek, J.P. Stein, and et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results J Urol 172 2004 2252 2255
39. S.A. Boorjian, R.H. Thompson, S. Siddiqui, and et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era J Urol 178 2007 864 870
40. A. Fleischmann, S. Schobinger, R. Markwalder, and et al. Prognostic factors in lymph node metastases of prostatic cancer patients: the size of the metastases but not extranodal extension independently predicts survival Histopathology 53 2008 468 475
41. M.C. Schumacher, F.C. Burkhard, G.N. Thalmann, A. Fleischmann, and U.E. Studer Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy Eur Urol 54 2008 344 352
42. A. Briganti, J.R. Karnes, L.F. Da Pozzo, and et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy Eur Urol 55 2009 261 270
43. K.A. Touijer, C.R. Mazzola, D.D. Sjoberg, P.T. Scardino, and J.A. Eastham Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy Eur Urol 65 2014 20 25
44. R. Seiler, U.E. Studer, K. Tschan, P. Bader, and F.C. Burkhard Removal of limited nodal disease in patients undergoing radical prostatectomy: long-term results confirm a chance for cure J Urol 191 2014 1280 1285
45. E.M. Messing, J. Manola, J. Yao, and et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. 2006 Lancet Oncol 7 2006 472 479
46. P.E. Spiess, A.K. Lee, J.E. Busby, and et al. Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome? BJU Int. 99 2007 321 325
47. L.F. Da Pozzo, C. Cozzarini, A. Briganti, and et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy Eur Urol 55 2009 1003 1011
48. A. Briganti, R.J. Karnes, L.F. Da Pozzo, and et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis Eur Urol 59 2011 832 840
49. F. Abdollah, R.J. Karnes, N. Suardi, and et al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer J Clin Oncol 32 2014 3939 3947
50. F.H. Schröder, K.H. Kurth, S.D. Fossa, and et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial) Eur Urol 55 2009 14 22
51. C.A. Lawton, K. Winter, D. Grignon, and M.V. Pilepich Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31 J Clin Oncol 23 2005 800 807
52. N. James, M. Spears, N.W. Clarke, and et al. Impact of node status and radiotherapy on failure-free survival in patients with newly diagnosed non-metastatic prostate cancer: data from >690 patients in the control arm of the STAMPEDE trial Radiat Oncol 90 Suppl 1 2014 S13
53. G.D. Steinberg, J.I. Epstein, S. Piantadosi, and P.C. Walsh Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987 J Urol 144 1990 1425 1432
54. L.R. Wiegand, M. Hernandez, L.L. Pisters, and P.E. Spiess Surgical management of lymph-node-positive prostate cancer: improves symptomatic control BJU Int 107 2011 1238 1242
55. A.C. Won, H. Gurney, G. Marx, P. De Souza, and M.I. Patel Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer BJU Int 112 2013 E250 E255
56. G. Aus, J. Hugosson, and L. Norlén Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent J Urol 154 1995 466 469
57. C. Piper, D. Porres, D. Pfister, and A. Heidenreich The role of palliative surgery in castration-resistant prostate cancer Curr Opin Support Palliat Care 8 2014 250 257
58. D. Leibovici, A.M. Kamat, C.A. Pettaway, and et al. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer J Urol 174 2005 2186 2190
59. S. Halabi, N.J. Vogelzang, S.S. Ou, and E.J. Small The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 cancer and leukemia group B trials J Urol 177 2007 531 534
60. S.H. Culp, P.F. Schellhammer, and M.B. Williams Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study Eur Urol 65 2014 1058 1066
61. N. Fossati, Q.D. Trinh, J. Sammon, and et al. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer. A SEER-based study Eur Urol 67 2015 3 6
62. C. Gratzke, J. Engel, and C.G. Stief Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry Eur Urol 66 2014 602 603
63. P. Sooriakumaran, T. Nyberg, O. Akre, and et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes BMJ 348 2014 g1502
64. M. Eisenberger, E.D. Crawford, B. Blumenstein, and et al. The prognostic significance of PSA in stage D2 patients Proc Am Soc Clin Oncol 14 1995 235
65. M. Hussain, C.M. Tangen, C. Higano, and et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162) J Clin Oncol 24 2006 3984 3990
66. E. Efstathiou, N.A. Abrahams, R.F. Tibbs, and et al. Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification Eur Urol 57 2010 1030 1038
67. R.J. Bryant, C. Verrill, and F.C. Hamdy The genomic diversity of prostate cancer: our Achilles heel explored Eur Urol 67 2015 823 824
68. C.J. Sweeney ECOG: CHAARTED - chemohormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer Clin Adv Hematol Oncol 4 2006 588 590
69. A.M. Aparicio, A.L. Harzstark, P.G. Corn, and et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer Clin Cancer Res 19 2013 3621 3630
70. O. Yossepowitch, S.E. Eggener, F.J. Bianco Jr., and et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods J Urol 178 2007 493 499
71. J.F. Ward, J.M. Slezak, M.L. Blute, E.J. Bergstralh, and H. Zincke Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome BJU Int 95 2005 751 756
72. H. Van Poppel, K. Vekemans, L. Da Pozzo, and et al. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001) Eur J Cancer 42 2006 1062 1067
73. C.C. Parker, M.R. Sydes, M.D. Mason, and et al. Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial BJU Int 111 2013 697 699
74. G. Attard, Sydes MR, M.D. Mason, and et al. Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE Trial Eur Urol 66 2014 799 802
75. Onze Lieve Vrouwe Gasthuis. ISRCTN06890529. A randomised study about the effect on survival of hormonal therapy plus local external radiation therapy in patients with primary diagnosed metastasized (M+) prostate cancer. http://www.controlled-trials.com/ISRCTN06890529
76. MD Anderson Cancer Center. NCT01751438. Best systemic therapy or best systemic therapy (BST) plus definitive treatment (radiation or surgery). http://clinicaltrials.gov/show/NCT01751438
77. H.I. Scher, S. Halabi, I. Tannock, and et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159